Pet Cancer Therapeutics Market Share

Statistics for the 2023 & 2024 Pet Cancer Therapeutics market share, created by Mordor Intelligence™ Industry Reports. Pet Cancer Therapeutics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Pet Cancer Therapeutics Industry

The pet cancer therapeutics market is slightly consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known. Some key market players are AB Science, Vivesto AB (AdvaVet, Inc), Boehringer Ingelheim GmbH (Merial), Elanco (VetDC), ELIAS Animal Health, Karyopharm Therapeutics, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook, and Zoetis among others.

Pet Cancer Therapeutics Market Leaders

  1. Boehringer Ingelheim GmbH (Merial)

  2. Zoetis

  3. Elanco (VetDC)

  4. ELIAS Animal Health

  5. Vivesto AB (AdvaVet, Inc)

*Disclaimer: Major Players sorted in no particular order

Pet Cancer Therapeutics Market Concentration

Pet Cancer Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)